Is it time to repurpose geroprotective diabetes medications for prevention of dementia?
作者信息
He Diana, Aleksic Sandra
机构信息
Department of Internal Medicine, Montefiore Medical Center, Bronx, New York, USA.
Department of Internal Medicine, Divisions of Endocrinology and Geriatrics, Albert Einstein College of Medicine, Bronx, New York, USA.
出版信息
J Am Geriatr Soc. 2023 Jul;71(7):2041-2045. doi: 10.1111/jgs.18405. Epub 2023 May 25.
Abstract
摘要
相似文献
1
Is it time to repurpose geroprotective diabetes medications for prevention of dementia?是时候将具有老年保护作用的糖尿病药物重新用于预防痴呆症了吗？
J Am Geriatr Soc. 2023 Jul;71(7):2041-2045. doi: 10.1111/jgs.18405. Epub 2023 May 25.
2
Diabetes Therapies for Dementia.痴呆症的糖尿病疗法。
Curr Neurol Neurosci Rep. 2019 Jul 12;19(8):58. doi: 10.1007/s11910-019-0973-4.
3
Study to investigate cognitive function in type 2 diabetes.研究2型糖尿病患者的认知功能。
AWHONN Lifelines. 2002 Feb-Mar;6(1):16-7. doi: 10.1111/j.1552-6356.2002.tb00011.x.
4
Metformin protects against dementia in diabetes.二甲双胍可预防糖尿病患者患痴呆症。
Nat Rev Neurol. 2023 Dec;19(12):711. doi: 10.1038/s41582-023-00900-4.
5
Neuroprotective properties of DPP-4i: A therapeutic target for dementia prevention in elderly diabetic patients?DPP-4i 的神经保护特性：老年糖尿病患者痴呆预防的治疗靶点？
J Diabetes Investig. 2023 Apr;14(4):525-527. doi: 10.1111/jdi.13972. Epub 2023 Jan 8.
6
Changes in Medication Use After Dementia Diagnosis in an Observational Cohort of Individuals with Diabetes Mellitus.糖尿病患者观察性队列中痴呆症诊断后用药情况的变化
J Am Geriatr Soc. 2017 Jan;65(1):77-82. doi: 10.1111/jgs.14429. Epub 2016 Sep 19.
7
Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways.新型治疗机会可改善帕金森病认知障碍 重点关注与糖尿病相关的途径
CNS Drugs. 2019 Feb;33(2):143-160. doi: 10.1007/s40263-018-0601-x.
8
Call for effective therapies for preventing dementia in people with type 2 diabetes.呼吁为2型糖尿病患者预防痴呆症寻找有效疗法。
Lancet Diabetes Endocrinol. 2024 Aug;12(8):510-513. doi: 10.1016/S2213-8587(24)00158-X. Epub 2024 Jun 17.
9
Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus.基于肠促胰岛素的疗法在2型糖尿病痴呆和中风治疗中的潜力
J Diabetes Investig. 2016 Jan;7(1):5-16. doi: 10.1111/jdi.12420. Epub 2015 Oct 3.
10
The Association Between Second-Line Oral Antihyperglycemic Medication on Types of Dementia in Type 2 Diabetes: A Nationwide Real-World Longitudinal Study.2 型糖尿病患者二线口服降糖药与痴呆类型的关联：一项全国范围真实世界纵向研究。
J Alzheimers Dis. 2021;81(3):1263-1272. doi: 10.3233/JAD-201535.
引用本文的文献
1
Heterogeneous treatment effects of GLP-1RAs and SGLT2is on risk of Alzheimer's disease and related dementia in patients with type 2 diabetes: Insights from a real-world target trial emulation.胰高血糖素样肽-1受体激动剂（GLP-1RAs）和钠-葡萄糖协同转运蛋白2抑制剂（SGLT2is）对2型糖尿病患者患阿尔茨海默病及相关痴呆风险的异质性治疗效果：来自真实世界目标试验模拟的见解
Alzheimers Dement. 2025 Jun;21(6):e70313. doi: 10.1002/alz.70313.
2
Glycated hemoglobin and body mass index as mediators of GLP-1RAs and Alzheimer's disease and related dementias in patients with type 2 diabetes.糖化血红蛋白和体重指数作为2型糖尿病患者中胰高血糖素样肽-1受体激动剂与阿尔茨海默病及相关痴呆症之间的中介因素
Alzheimers Dement. 2025 Apr;21(4):e70161. doi: 10.1002/alz.70161.
3
GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias.用于2型糖尿病及阿尔茨海默病和相关痴呆症的胰高糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂药物
JAMA Neurol. 2025 May 1;82(5):439-449. doi: 10.1001/jamaneurol.2025.0353.
4
Trends in Co-morbid Dementia and Chronic Kidney Disease.共病性痴呆与慢性肾脏病的趋势
J Gen Intern Med. 2025 Jan 14. doi: 10.1007/s11606-024-09069-y.
5
Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study.40-69 岁 2 型糖尿病成人中钠-葡萄糖共转运蛋白 2 抑制剂与二肽基肽酶-4 抑制剂起始治疗后痴呆风险的比较：基于人群的队列研究。
BMJ. 2024 Aug 28;386:e079475. doi: 10.1136/bmj-2024-079475.
6
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study.胰高血糖素样肽-1受体激动剂与2型糖尿病患者的帕金森病风险：一项基于人群的队列研究
Mov Disord. 2024 Nov;39(11):1960-1970. doi: 10.1002/mds.29992. Epub 2024 Aug 27.
本文引用的文献
1
Onset age of diabetes and incident dementia: A prospective cohort study.糖尿病发病年龄与痴呆症发病率：一项前瞻性队列研究。
J Affect Disord. 2023 May 15;329:493-499. doi: 10.1016/j.jad.2023.02.138. Epub 2023 Mar 2.
2
Newer glucose-lowering drugs and risk of dementia: A systematic review and meta-analysis of observational studies.新型降糖药物与痴呆风险：观察性研究的系统评价和荟萃分析。
J Am Geriatr Soc. 2023 Jul;71(7):2096-2106. doi: 10.1111/jgs.18306. Epub 2023 Feb 23.
3
Association of Race and Ethnicity With Incidence of Dementia Among Older Adults.种族和民族与老年人痴呆症发病率的关联。
JAMA. 2022 Apr 19;327(15):1488-1495. doi: 10.1001/jama.2022.3550.
4
Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs.SGLT2 抑制剂和 GLP-1 受体激动剂的利用率及其在动脉粥样硬化性心血管疾病和 2 型糖尿病患者中的医疗机构间差异：来自退伍军人事务部的观察。
Diabetes Care. 2022 Feb 1;45(2):372-380. doi: 10.2337/dc21-1815.
5
Neuroprotective Effect of SGLT2 Inhibitors.SGLT2 抑制剂的神经保护作用。
Molecules. 2021 Nov 28;26(23):7213. doi: 10.3390/molecules26237213.
6
IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.国际糖尿病联盟（IDF）糖尿病地图集：2021 年全球、区域和国家糖尿病患病率估算值以及 2045 年预测值。
Diabetes Res Clin Pract. 2022 Jan;183:109119. doi: 10.1016/j.diabres.2021.109119. Epub 2021 Dec 6.
7
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation.用于阿尔茨海默病的血液生物标志物：迈向临床应用
Lancet Neurol. 2022 Jan;21(1):66-77. doi: 10.1016/S1474-4422(21)00361-6. Epub 2021 Nov 24.
8
Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US.美国糖尿病患者中钠-葡萄糖共转运蛋白 2 抑制剂使用与种族/民族、性别和社会经济地位的关联。
JAMA Netw Open. 2021 Apr 1;4(4):e216139. doi: 10.1001/jamanetworkopen.2021.6139.
9
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
10
Metformin Use Is Associated With Slowed Cognitive Decline and Reduced Incident Dementia in Older Adults With Type 2 Diabetes: The Sydney Memory and Ageing Study.二甲双胍的使用与 2 型糖尿病老年患者认知能力下降减缓及痴呆发生减少相关：悉尼记忆与老龄化研究。
Diabetes Care. 2020 Nov;43(11):2691-2701. doi: 10.2337/dc20-0892. Epub 2020 Sep 23.
Zotero 插件